Sunzen Group Berhad successfully concluded its Nineteenth Annual General Meeting with a strong shareholder participation and approval of all resolutions tabled.
Among the key resolutions approved was the Directors’ fees and benefits for the extended financial period of 1 January 2024 to 30 June 2025, reflecting the Board’s commitment to fostering a high level of governance and oversight. Shareholders also approved the re-election of three directors, namely Mr. Ching Chee Pun, Mr. Lee Yew Weng, and Puan Aida Lim Binti Abdullah, ensuring continuity in leadership and strategic direction for Sunzen.
In a landmark decision, shareholders approved a special resolution to rename the company from “Sunzen Biotech Berhad” to “Sunzen Group Berhad.” This rebranding signals the Group’s evolution into a diversified entity encompassing health, medical devices and services, and loan financing, while maintaining its commitment to meeting customer needs and demands over the long term.
